SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is trending amid community excitement, with many highlighting bullish technical patterns and anticipating a potential CoinMarketCap (CMC) listing. Discussions revolve around the strong community and the token's potential within the Solana ecosystem. Some users express concerns about potential pump-and-dump schemes.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining traction, with community members actively chanting "caw caw" and highlighting its multi-chain presence across Solana, BSC, CRO, and Ethereum (BASE). The coin's deflationary mechanism and organic community growth are key talking points, as well as its potential to disrupt the meme coin landscape, maybe even toppling $SHIB and $DOGE. Recent listings across a dozen exchanges appear to be improving liquidity.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is trending amidst community discussions about its potential, particularly after its integration with Abstract Chain and Shogun, enabling cross-chain triggers and on-chain AI automation. Some community members are speculating about future Coinbase listings and anticipating a price surge, while others debate potential price drops and the influence of certain traders. The migration away from $PRQ and its impact on the token's price is also a hot topic.

Green Satoshi Token

Green Satoshi Token is trending as the community anticipates a potential pump, fueled by increased volume and technical indicators suggesting a possible breakout. Many are pointing to its low market cap and historical price movements, expressing belief that GSTSOL is coiling up for a significant run, reminiscent of its past performance. Some users are also referencing its association with the STEPN app.

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as analysts adjust price targets and ratings, following news of Piper Sandler and Stephens & Co. setting overweight ratings. The community highlights potential for new store openings and expansion into electric vehicle services, viewing it as a safe, long-term investment. Bullish sentiment suggests potential to test all-time highs, with some eyeing it as an 'easy money' opportunity.

What is the project about?   Horizen is a modular privacy-first platform designed to make privacy technology, such as zero-knowledge proofs and TEEs accessible and usable across the web. Originally launched in 2017 as a fair launch, non-ICO project, Horizen is now undergoing a major evolution with the launch of Horizen 2.0, a next-generation Layer 3 (L3) appchain deployed on Base, the Ethereum Layer 2 developed by Coinbase.  Horizen 2.0 is built as an Ethereum-aligned Layer 3 appchain on Base, inheriting Ethereum's security while implementing its own application-level integrity guarantees.    Key components of Horizen’s security model include:  Ethereum-Aligned Security: As an appchain deployed on Base, Horizen 2.0 benefits from Base’s rollup security and settlement on Ethereum, ensuring robust finality and composability with other L2 and L3 applications.  Simplified and Secure Architecture: Unlike Horizen’s previous iterations (which used a hybrid PoW/PoS model), Horizen 2.0 focuses on application-level security, decentralization of its privacy layers, and composability with existing infrastructure — reducing complexity and increasing user safety.  Decentralized Privacy Stack: Horizen’s focus on decentralizing privacy infrastructure (e.g., decentralized proof generation) allows for modular, secure applications that uphold data confidentiality without compromising performance.    What makes your project unique?  Privacy-first Approach: Horizen integrates a diverse stack of privacy-enhancing technologies (PETs) — including zero-knowledge proofs (ZKPs), trusted execution environments (TEEs), attribute-based encryption (ABE), multi-party computation (MPC), and fully homomorphic encryption (FHE) — to deliver scalable, flexible, and future-ready privacy solutions across its platform.  First Privacy Appchain on Base: As an L3 on Base, Horizen benefits from Ethereum’s security and Base’s scalability, while enabling a privacy layer for any app on the network. This unlocks new possibilities for private identity, DeFi, onchain gaming, and compliant confidential transactions.  Zero-Knowledge, Without the Trade-Offs: Horizen 2.0 scales ZK privacy and verification by integrating with leading zk infrastructure providers such as Fermah, zkVerify, and Singularity, optimizing proof generation for performance, cost-efficiency, and developer usability.  Token Utility Expansion: ZEN’s updated tokenomics allocates 5 million unminted tokens toward strategic ecosystem growth. ZEN powers DAO governance, serves as a payment token in privacy apps, and supports a sustainability fund to accelerate privacy innovation.  Developer-Centric Design: With EVM compatibility, privacy-friendly tooling, and the ability to embed privacy directly into smart contracts, Horizen allows developers to build privacy-first apps without requiring deep cryptographic expertise.  DAO-Led Governance: Governed by the Horizen DAO and shaped through community proposals (ZENIPs), Horizen is evolving as a fully decentralized protocol with transparent development and decision-making.    What can your coin/token be used for?  Horizen 2.0 delivers performance, privacy, and scalability for developers building privacy-enabled and compliance-friendly applications, with significantly reduced cost and latency.  At the core of the ecosystem is ZEN, the native utility token used for governance, accessing privacy services, and fueling zkApp interactions. With its migration to Base, ZEN becomes an ERC-20 token, improving liquidity, interoperability, and composability across the broader Ethereum ecosystem.

ZenCash

ZEN is trending due to its migration to the Base chain and potential for private DeFi applications, sparking bullish sentiment. Community members are actively discussing entry points and price targets, while also weighing in on its potential compared to other privacy coins. The focus remains on how the move to Base will impact ZEN's utility and adoption within the Ethereum ecosystem.

Akira Labs builds tools to enhance users’ trading experience across multiple blockchains. Our Telegram-based bot allows automated trades, real-time copy trading, and whale tracking, giving traders speed, transparency, and actionable insights. We aim to create a complete ecosystem where users can track markets, make informed decisions, and participate in exclusive products available only to token holders. “Empowering traders"

AKIRA LABS

AKIRA Labs is trending, with community members highlighting its consistent growth, solid volume, and strong community. Many suggest adding $AKIRA to watchlists, noting that "smart money is paying attention" and that "big things ahead across these tickers." The community is also actively discussing the relationship between $AKIRA and $UPDOG.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as the community discusses its pending merger with Infleqtion, a quantum computing company, and its potential to be undervalued compared to peers like $IONQ and $QBTS. Bullish sentiment is building around Infleqtion's existing government contracts and partnerships, including one with $NVDA, fueling speculation it could become a major player in the quantum space. Some investors are noting the relatively small float and anticipating significant price movement as more people discover the stock.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is experiencing increased attention, potentially mirroring the movements of Zcash, with community members pointing to Elliott Wave analysis suggesting a possible retracement toward the $44-$50 range.  Discussions revolve around its ability to hold gains and comparisons to other cryptocurrencies, with some users anticipating a significant pump. Additionally, recent partnerships and integrations, like the one with Vultisig, are being highlighted as potential catalysts.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

10x Genomics Inc - Ordinary Shares - Class A

TXG is trending amid analyst upgrades and positive developments in its spatial biology technology, with the community actively discussing its potential for growth and dominance in the single-cell analysis market. Some investors are reacting to insider selling and debating its current valuation, while others highlight its long-term potential and recent breakthroughs in gene panel technology. Patent litigation news is also contributing to the stock's increased attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy

Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Adagene (ADAG) This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and CorMedix (CRMD) have performed compared to their sector so far this year.

Adagene Inc. (ADAG) on Tuesday said that it received directions from the U.S. Food and Drug Administration on further clinical development of its investigational drug Muzastotug in combination with Merck’s (MRK) cancer drug Keytruda in patients with microsatellite stable colorectal cancer (MSS CRC).<a href="https://stocktwits.com/symbol/ADAG">ADAG shares </a>were trading 2% lower in the pre-market session at the time of writing.Adagene had a <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.adagene.com/news-releases/news-release-details/adagene-announces-regulatory-update-clinical-development-plan">meeting</a> with the FDA and received written feedback, the company said. &nbsp;During the meeting, it was decided that future trials will enroll late-line patients with MSS CRC that has not spread to the liver. Mid-stage trials will randomize patients to either 10 mg/kg or 20 mg/kg of the drug in combination with Keytruda, aiming to identify which of the two doses will be used in the late-stage trial.Approximately 30 patients will be enrolled in each arm of the mid-stage study and will seek to evaluate overall response rate, duration of response, progression-free survival, and overall survival.In a late-stage study, the company stated that it will observe whether the drug primarily leads to an improvement in overall survival.Neither the mid-stage nor the late-stage trial needs an arm studying the drug as a monotherapy without Keytruda, the company added.Microsatellite stable colorectal cancer refers to colorectal tumors that do not exhibit microsatellite instability, meaning their DNA is relatively stable.Adagene CEO Peter Luo thanked Merck for supplying Keytruda for the trials.“Our Phase 1b/2 trial has produced robust dose-dependent efficacy data with a potential best-in-class safety profile, identifying two optimized dose levels for the Phase 2, consistent with Project Optimus,” he added.On Stocktwits, retail sentiment around jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume increased from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_15_at_8_29_09_AM_png_2a79db34cd.webp" alt="ADAG's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 15, 2025 | Source: Stocktwits" width="1364" height="128"><figcaption>ADAG's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 15, 2025 | Source: Stocktwits</figcaption></figure>ADAG stock is down by 8% this year and by about 33% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jane-fraser-calls-services-citi-crown-jewel-as-profit-jumps-25-percent-q2-results-beat-estimates/ch8QdmhR5FK">Jane Fraser Calls Services Citi’s ‘Crown Jewel’ As Profit Jumps 25%, Q2 Results Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic

Neither the mid-stage nor the late-stage trial of Adagene’s drug needs an arm studying the drug as a monotherapy without Merck’s Keytruda, the company said.

Equity

Neither the mid-stage nor the late-stage trial of Adagene’s drug needs an arm studying the drug as a monotherapy without Merck’s Keytruda, the company said.


Is McKesson (MCK) Outperforming Other Medical Stocks This Year?

Adani Group stocks drop after U.S. probe report on alleged Iranian LPG imports

Investing.com -- Shares of Adani Group companies declined on Tuesday following a Wall Street Journal (WSJ) report that U.S. authorities are investigating whether the conglomerate imported Iranian liquefied petroleum gas (LPG) through its Mundra port in Gujarat, potentially violating U.S. sanctions.

Adagene Inc. (NASDAQ:ADAG) Short Interest Update

Adagene Inc. (NASDAQ:ADAG - Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 22,300 shares, a growth of 9.9% from...

Adagene (ADAG, $3.24) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that ADAG's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Adagene Inc. (NASDAQ:ADAG - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 22,300 shares, an...

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Adagene Inc - ADR

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

ADAG
Adagene Inc - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest ADAG News

ADAG Adagene Inc - ADR